[Moving Trailer Voice] This Halloween: They always come back....
The latest revival is belantamab mafodotin, FDA approved...again. After being vanquished in DREAMM3, it returned in DREAMM7 and even Daratumumab (in combination with Vd) couldn't overcome this blindingly effective drug (in combination with Vd).
This pod reviews belantamab mafodotin's checkered past and wonders what the sequels may have in store for us.
--------
14:23
--------
14:23
ESMO 2025
This week's episode recaps some highlights from ESMO 2025:
1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery
2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer
3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer
4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer
5. Dynamic-III: ctDNA guide de-escalation or escalation of chemotherapy in stage III colon cancer
6. HARMONi-6: an excuse to talk about ivonescimab, a bispecific antibody unlike any other currently FDA approved
--------
24:43
--------
24:43
IL-2
IL-2, one of the founding fathers of our current immunotherapy landscape, is discussed.
--------
7:59
--------
7:59
Maintenance Therapy in Small Cell Lung Cancer
Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab?
IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6
DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00480-2
--------
12:03
--------
12:03
PARAMOUNT - Maintenance Pemetrexed
Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in NSCLC.
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Ireland